Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo

Y. Saikawa, T. Kubota, T. H. Kuo, H. Tanino, S. Kase, Toshiharu Furukawa, M. Watanabe, K. Ishibiki, M. Kitajima, R. M. Hoffman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The antitumor activity of a sequential combination of 5-fluorouracil (5-FU) and carboplatin (JM-8) was evaluated using gastric cancer cell lines in vitro and in vivo. In the in vitro study the sequence of 5-FU followed by JM-8 showed higher antitumor activity than that of the reverse sequence. The sequence of 5-FU at 5 μg/ml for 24 h followed by 5 μg/ml JM-8 for 24 h showed antitumor activity almost equivalent to that of 10 μg/ml 5-FU for 24 h and higher activity than that of 10 μg/ml JM-8 for 24 h on two cell lines. To evaluate the antitumor activity and toxicity of 5-FU and JM-8 in vivo BALB/cA nu/nu mice bearing human gastric cancer xenografts St-15, St-40 and SC-1-NU were administered 5-FU and JM-8 intraperitoneally. The sequence of 5-FU prior to JM-8 showed higher antitumor activity than that of the reverse sequence on all the xenografts and simultaneous administration of 5-FU and JM-8 showed the most potent antitumor activity on St-40 and SC-1-NU. On the other hand the sequence of 5-FU before JM-8 showed the lowest toxicity in all the treated groups in terms of death rate, body weight loss, and spleen weight loss. This combination is thought to be a promising chemotherapy regimen showing high antitumor activity without an increment of toxicity.

Original languageEnglish
Pages (from-to)461-464
Number of pages4
JournalAnticancer Research
Volume14
Issue number2 A
Publication statusPublished - 1994

Fingerprint

Carboplatin
Fluorouracil
Stomach Neoplasms
Cell Line
Heterografts
Weight Loss
In Vitro Techniques
Spleen
Body Weight
Drug Therapy
Mortality

Keywords

  • 5-fluorouracil
  • Carboplatin
  • Human gastric cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saikawa, Y., Kubota, T., Kuo, T. H., Tanino, H., Kase, S., Furukawa, T., ... Hoffman, R. M. (1994). Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. Anticancer Research, 14(2 A), 461-464.

Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. / Saikawa, Y.; Kubota, T.; Kuo, T. H.; Tanino, H.; Kase, S.; Furukawa, Toshiharu; Watanabe, M.; Ishibiki, K.; Kitajima, M.; Hoffman, R. M.

In: Anticancer Research, Vol. 14, No. 2 A, 1994, p. 461-464.

Research output: Contribution to journalArticle

Saikawa, Y, Kubota, T, Kuo, TH, Tanino, H, Kase, S, Furukawa, T, Watanabe, M, Ishibiki, K, Kitajima, M & Hoffman, RM 1994, 'Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo', Anticancer Research, vol. 14, no. 2 A, pp. 461-464.
Saikawa, Y. ; Kubota, T. ; Kuo, T. H. ; Tanino, H. ; Kase, S. ; Furukawa, Toshiharu ; Watanabe, M. ; Ishibiki, K. ; Kitajima, M. ; Hoffman, R. M. / Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. In: Anticancer Research. 1994 ; Vol. 14, No. 2 A. pp. 461-464.
@article{6050f68f1c1a44e68799dc3df2388f10,
title = "Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo",
abstract = "The antitumor activity of a sequential combination of 5-fluorouracil (5-FU) and carboplatin (JM-8) was evaluated using gastric cancer cell lines in vitro and in vivo. In the in vitro study the sequence of 5-FU followed by JM-8 showed higher antitumor activity than that of the reverse sequence. The sequence of 5-FU at 5 μg/ml for 24 h followed by 5 μg/ml JM-8 for 24 h showed antitumor activity almost equivalent to that of 10 μg/ml 5-FU for 24 h and higher activity than that of 10 μg/ml JM-8 for 24 h on two cell lines. To evaluate the antitumor activity and toxicity of 5-FU and JM-8 in vivo BALB/cA nu/nu mice bearing human gastric cancer xenografts St-15, St-40 and SC-1-NU were administered 5-FU and JM-8 intraperitoneally. The sequence of 5-FU prior to JM-8 showed higher antitumor activity than that of the reverse sequence on all the xenografts and simultaneous administration of 5-FU and JM-8 showed the most potent antitumor activity on St-40 and SC-1-NU. On the other hand the sequence of 5-FU before JM-8 showed the lowest toxicity in all the treated groups in terms of death rate, body weight loss, and spleen weight loss. This combination is thought to be a promising chemotherapy regimen showing high antitumor activity without an increment of toxicity.",
keywords = "5-fluorouracil, Carboplatin, Human gastric cancer",
author = "Y. Saikawa and T. Kubota and Kuo, {T. H.} and H. Tanino and S. Kase and Toshiharu Furukawa and M. Watanabe and K. Ishibiki and M. Kitajima and Hoffman, {R. M.}",
year = "1994",
language = "English",
volume = "14",
pages = "461--464",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo

AU - Saikawa, Y.

AU - Kubota, T.

AU - Kuo, T. H.

AU - Tanino, H.

AU - Kase, S.

AU - Furukawa, Toshiharu

AU - Watanabe, M.

AU - Ishibiki, K.

AU - Kitajima, M.

AU - Hoffman, R. M.

PY - 1994

Y1 - 1994

N2 - The antitumor activity of a sequential combination of 5-fluorouracil (5-FU) and carboplatin (JM-8) was evaluated using gastric cancer cell lines in vitro and in vivo. In the in vitro study the sequence of 5-FU followed by JM-8 showed higher antitumor activity than that of the reverse sequence. The sequence of 5-FU at 5 μg/ml for 24 h followed by 5 μg/ml JM-8 for 24 h showed antitumor activity almost equivalent to that of 10 μg/ml 5-FU for 24 h and higher activity than that of 10 μg/ml JM-8 for 24 h on two cell lines. To evaluate the antitumor activity and toxicity of 5-FU and JM-8 in vivo BALB/cA nu/nu mice bearing human gastric cancer xenografts St-15, St-40 and SC-1-NU were administered 5-FU and JM-8 intraperitoneally. The sequence of 5-FU prior to JM-8 showed higher antitumor activity than that of the reverse sequence on all the xenografts and simultaneous administration of 5-FU and JM-8 showed the most potent antitumor activity on St-40 and SC-1-NU. On the other hand the sequence of 5-FU before JM-8 showed the lowest toxicity in all the treated groups in terms of death rate, body weight loss, and spleen weight loss. This combination is thought to be a promising chemotherapy regimen showing high antitumor activity without an increment of toxicity.

AB - The antitumor activity of a sequential combination of 5-fluorouracil (5-FU) and carboplatin (JM-8) was evaluated using gastric cancer cell lines in vitro and in vivo. In the in vitro study the sequence of 5-FU followed by JM-8 showed higher antitumor activity than that of the reverse sequence. The sequence of 5-FU at 5 μg/ml for 24 h followed by 5 μg/ml JM-8 for 24 h showed antitumor activity almost equivalent to that of 10 μg/ml 5-FU for 24 h and higher activity than that of 10 μg/ml JM-8 for 24 h on two cell lines. To evaluate the antitumor activity and toxicity of 5-FU and JM-8 in vivo BALB/cA nu/nu mice bearing human gastric cancer xenografts St-15, St-40 and SC-1-NU were administered 5-FU and JM-8 intraperitoneally. The sequence of 5-FU prior to JM-8 showed higher antitumor activity than that of the reverse sequence on all the xenografts and simultaneous administration of 5-FU and JM-8 showed the most potent antitumor activity on St-40 and SC-1-NU. On the other hand the sequence of 5-FU before JM-8 showed the lowest toxicity in all the treated groups in terms of death rate, body weight loss, and spleen weight loss. This combination is thought to be a promising chemotherapy regimen showing high antitumor activity without an increment of toxicity.

KW - 5-fluorouracil

KW - Carboplatin

KW - Human gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=0028339970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028339970&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 461

EP - 464

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -